December 1, 2021 -- Immunicum and PCI Biotech will jointly research introducing tumor-independent immune targets into the tumor microenvironment with vaccination or adoptive immunotherapies as a possibility of overcoming current hurdles in cancer immunotherapy.
The tumor independent-antigen concept developed by Immunicum could benefit from PCI Biotech's antigen-delivery technologies based on photochemical internalization (PCI), according to the two companies. Following the initial success of in vitro results, the companies will evaluate the novel therapeutic concept in animal models.
Immunicum is focused on hard-to-treat established tumors and preventing cancer recurrence. PCI Biotech specializes in the development and commercialization of novel therapies for the treatment of cancer through its innovative PCI technology platform.
No financial details of the collaboration declarations were disclosed.
Copyright © 2021 scienceboard.net